1SHIMIZU E, NAKAURA Y, MUKAI J, et al Parmacokineties of bronchial artery infusion of mitomycin in patients with non-small cell lung cancer[J], Eur J Cancer,1991, 27(2):1046-1049. 被引量：1
2SAUER H, FUGER K, BLUMENSTEIN M, et al,Modulation of cytotoxicity of cytostatic drugs by hemodialysis in vivo and in vivio[J], Cancer Test Rev, 1990, 17 (2) : 3293-3300. 被引量：1
3McKEAGE M J. Lobaplatin: a new antitumour platinum drug[J], Expert Opin Investig Drugs,2001, 10( 1):119-128. 被引量：1
4WELINK J, BOVEN E, VERMORKEN J B, et al,Pharmacokinetics and pharmacodynamics of lobaplatin (D-19466) in patients with advanced solid tumors, including patients with impaired renal of liver function[J]. Clin Cancer Res, 1999, 5(9): 2349-2358. 被引量：1
5SARIS C P, VAART P J, RIETBROEK. R C, et al. In vitro formation of DNA adducts by cisplatin, lobaplatin and oxaliplatin in calf thymus DNA in solution and in cultured human cells[J], Carcinogenesis, 1996, 17(12) :2763-2769. 被引量：1
6KIRPENSTEIJN J, TESKE E, KIK M, et al. Lobaplatin as an adjuvant chemotherapy to surgery in canine appendicular osteosarcoma: a phase Ⅱ evaluation[J]. Anticancer Res, 2002,22(5) ,2765-2770. 被引量：1
7STERNBERG C N, de MULDER P, FOSSA S, et al.Lobaplatin in advanced urothelial tract tumors[J]. Ann Oncol,1997, 8(7):695-696. 被引量：1
